S1 Biopharma, Inc. products

S1 Biopharma’s first-in-class lead product, Lorexys, targets hypoactive sexual desire disorder (HSDD) in women, the most common type of female sexual dysfunction. Lorexys is designed to restore the balance of three neurotransmitters – dopamine, serotonin and norepinephrine – that are known to regulate sexual inhibition and sexual excitation. An oral, non-hormonal, fixed-dose combination of two antidepressants, bupropion and trazodone, Lorexys is formulated with a ratio that is precisely balanced to neutralize the side effects of its individual components and maximize efficacy.

S1B-307 is at the IND / Phase 1 preparatory stage for the treatment of orgasmic disorder (OD). S1 Biopharma expects 505(b)(2) status to be granted for this candidate.

Orexa is S1 Biopharma’s first therapy for erectile dysfunction (ED).

S1B-3006 is being developed to treat low desire and other sexual issues that are associated with a general medical condition. It is not uncommon for medical conditions to be accompanied by low desire. For example, low desire affects 90% of patients with breast cancer and 50% of those with diabetes.